Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-05-14FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Somerset Therapeutics, LLC)
FDA approved a supplemental application for verapamil hydrochloride, a generic version, filed by Somerset Therapeutics, LLC.
-
CLINICAL_TRIALS trial_result · 2020-05-14Clinical Trial Update: Clinical Study to Evaluate the Efficacy and Safety of CKD-348(CKD-828, D326, D337) Tablet [Phase 3]
Phase 3 clinical trial update evaluating the efficacy and safety of CKD-348 in hypertension and dyslipidemias.
-
CLINICAL_TRIALS trial_result · 2020-05-12Clinical Trial Update: To Evaluate Real-world Safety, Effectiveness and Appropriate Use of Micatrio® Combination Tablets Treatment in Patients With Hypertension
Clinical trial update evaluating real-world safety and effectiveness of Micatrio combination tablets for hypertension; completed with result…
-
CLINICAL_TRIALS trial_result · 2020-05-06Clinical Trial Update: Renal Nerves Stimulation Study [Phase 2]
Phase 2 clinical trial update for renal nerve stimulation in hypertension (renal denervation) has completed.
-
FDA approval · 2020-05-05FDA Approved: VALSARTAN — Supplemental Application (Jubilant Cadista Pharmacuticals Inc.)
The FDA approved Jubilant Cadista's supplemental application for the generic drug valsartan. Valsartan is used to treat hypertension, heart …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2020-04-29FDA Approved: LISINOPRIL — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.(780779901))
FDA approved a supplemental application for lisinopril from Heritage Pharmaceuticals d/b/a Avet Pharmaceuticals, advancing an update to an e…
-
FDA approval · 2020-04-29FDA Approved: DILTIAZEM HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for diltiazem hydrochloride (generic) under ANDA074185.
-
CLINICAL_TRIALS trial_result · 2020-04-29Clinical Trial Update: Drug-eluting Balloon for Treatment of Non-atherosclerotic Renal Artery Stenosis [Phase 3]
Phase 3 clinical trial update for a drug-eluting balloon aimed at treating non-atherosclerotic renal artery stenosis in patients with renova…
-
FDA approval · 2020-04-28FDA Approved: DILTIAZEM HYDROCHLORIDE — Original Application (Accord Healthcare, Inc.)
FDA approved Accord Healthcare's diltiazem hydrochloride as an original generic application (ANDA) for the established indications of diltia…
-
FDA approval · 2020-04-27FDA Approved: LISINOPRIL — Supplemental Application (Solco healthcare U.S., LLC)
FDA approved a supplemental application for lisinopril from Solco Healthcare U.S., LLC, approving a generic lisinopril product.
-
FDA approval · 2020-04-27FDA Approved: LISINOPRIL — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for lisinopril submitted by Quallent Pharmaceuticals Health LLC.
-
CLINICAL_TRIALS trial_result · 2020-04-16Clinical Trial Update: A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension [Phase 2]
Phase 2 trial evaluating IW-1973, a stimulator of soluble guanylate cyclase (sGC), in patients with stable type 2 diabetes and hypertension …
-
FDA approval · 2020-04-14FDA Approved: ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Taro Pharmaceuticals U.S.A., Inc.)
The FDA approved a supplemental application for Enalapril Maleate and Hydrochlorothiazide from Taro Pharmaceuticals U.S.A., Inc., enabling a…
-
FDA approval · 2020-04-14FDA Approved: TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE — Supplemental Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved a supplemental application to authorize a fixed-dose combination of trandolapril and verapamil hydrochloride, submitted by …
-
FDA approval · 2020-04-14FDA Approved: ENALAPRIL MALEATE — Supplemental Application (Northstar RxLLC)
FDA approved a supplemental application for Enalapril maleate from Northstar RxLLC under an ANDA.
-
FDA approval · 2020-04-14FDA Approved: ENALAPRIL MALEATE — Supplemental Application (Northstar RxLLC)
FDA approved a supplemental application for enalapril maleate (generic enalapril) submitted by Northstar RxLLC, effectively granting a suppl…
-
FDA approval · 2020-04-13FDA Approved: TELMISARTAN AND HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approves Aurobindo Pharma Limited's supplemental application for a generic telmisartan and hydrochlorothiazide combination tablet for tr…
-
FDA approval · 2020-04-10FDA Approved: TELMISARTAN — Supplemental Application (Solco Healthcare US, LLC)
The FDA approved a supplemental application for Telmisartan from Solco Healthcare US, LLC.
-
FDA label_change · 2020-04-08FDA Approved: VALSARTAN — Supplemental Application (Macleods Pharmaceuticals Limited)
The FDA approved a supplemental application for valsartan from Macleods Pharmaceuticals Limited, indicating changes to the product labeling.
-
CLINICAL_TRIALS trial_result · 2020-04-08Clinical Trial Update: Bedtime ACEIs/ARBs Versus Morning ACEIs/ARBs for Reverting Non-dipping Hypertension [Phase 4]
Phase 4 trial update on bedtime versus morning dosing of ACEIs/ARBs for reverting non-dipping hypertension was terminated.
-
CLINICAL_TRIALS trial_result · 2020-04-01Clinical Trial Update: MediBeat - HeartBeat Observation Trial [NA]
Clinical trial update for MediBeat HeartBeat Observation Trial (NCT04082819) completed with results posted in 2020.
-
FDA approval · 2020-03-31FDA Approved: METOPROLOL SUCCINATE — Original Application (Nivagen Pharmaceuticals, Inc.)
FDA approved an original ANDA for metoprolol succinate, a generic product manufactured by Nivagen Pharmaceuticals, Inc.
-
FDA approval · 2020-03-27FDA Approved: VERAPAMIL HYDROCHLORIDE — Supplemental Application (Nivagen Pharmaceuticals, Inc.)
FDA approved a supplemental application for verapamil hydrochloride from Nivagen Pharmaceuticals, Inc., updating regulatory status for this …
-
EMA guidance · 2020-03-27EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic
The EMA advises patients to continue taking medicines for hypertension, heart, or kidney disease during the COVID-19 pandemic, addressing sa…
-
CLINICAL_TRIALS trial_result · 2020-03-27Clinical Trial Update: Renal Denervation for Management of Drug-Resistant Hypertension [NA]
Clinical trial update on renal denervation for drug-resistant hypertension completed with posted results.